Advertisement

Lupin receives EIR for Nagpur plant from US FDA

Follow The Hawk on Google News+ Follow

Advertisement


Mumbai: Pharma major Lupin on Monday announced that it has received an Establishment Inspection Report (EIR) from the US health regulator ''Food and Drug Administration (FDA) for its manufacturing plant in Nagpur.

The inspection for the facility was carried out by The US Food and Drug Administration (FDA) between January 6-10 this year.

Advertisement

"We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites," said Nilesh Gupta, Managing Director, Lupin.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the US, India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

Lupin is the third largest pharmaceutical company in the US by prescriptions and in India by global revenues. The Company invests 9.6 per cent of its revenues on research and development.

Advertisement

It has 15 manufacturing sites and seven research centres, with more than 20,000 professionals working globally.

--IANS

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST